QURE Share Price Performance
US$27.79
20.00 (256.74%)
63.0% undervalued intrinsic discount
US$75.09
Fair Value
Price US$27.79
AnalystConsensusTarget US$75.09
Fair ValueUS$75.09
Share PriceUS$27.79
63.0% undervalued intrinsic discount
uniQure N.V. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 25 Fair Values set on narratives written by author
QURE Community Narratives
AN
Fair Value US$75.09 63.0% undervalued intrinsic discount
QURE: Pivotal Three-Year Huntington’s Data Will Drive Approval and Market Uptake
1users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
QURE: Pivotal Three-Year Huntington’s Data Will Drive Approval and Market Uptake
Key Takeaways Accelerated approval of AMT-130 for Huntington's could significantly boost future revenues as it would be a pioneering treatment. Strategic financial actions and strong cash reserves provide resilience and flexibility, supporting pipeline advancement and likely improving margins.Read more
1users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
US$75.09
63.0% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
223.39% p.a.
Profit Margin
20.13%
Future PE
62.72x
Share price in 2028
US$91.09
Snowflake Analysis
uniQure N.V. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 10, 2025
- -3.23
- -850.06%
- -1,387.98%
- -12,668.0%
About QURE
- Founded
- 1998
- Employees
- 209
- CEO
- WebsiteView website
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
